SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Gilead Science (GILD) Followers
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
961 87 0 GILD
Emcee:  SybilNicolas Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61 Merck's Recombivax for HBV is used prophylactically, and is regarded as effJohn Metcalf-10/17/1996
60 If the viral load returned to pretreatment levels after discontinuation of the Doug Meetmer-10/17/1996
59 Doug, GS840 is a non-nucleoside reverse transcriptease inhibitor (NNRTI). The John Metcalf-10/16/1996
58 Hello John, What is unclear to me is whether Gilead's drug for HBV will coDoug Meetmer-10/16/1996
57 Michael Collins demands an answer to his previous post! If he will refrain froJohn Metcalf-10/15/1996
56 Hey where did all the Gilead followers go???? Could you please answer my quesMichael Collins-10/15/1996
55 I think Gilead will be one of the best biotechs to hold long-term. I don'tMichael Collins-10/2/1996
54 Boyce, I appreciated your response! GILD is after all of those nasty viral STD&V.-10/1/1996
53 Another GILD follower. Virology was my game at one time, and Ive heard several Boyce Burge-10/1/1996
52 Ross & Gilead followers: Yes, this was the info that Joe Kiernan on CNBC waV.-10/1/1996
51 GILD and Hoffmann-La Roche Inc. are in a co-promotion agreement for Roche'sRoss Abrams-9/30/1996
50 My feelings are when in doubt, to call the company directly to seek an answer.Ross Abrams-9/20/1996
49 A very astute analysis of the situation. Thanks for taking the time to call thDoug Meetmer-9/20/1996
48 By now you should all know that the two patients that were "hyped" byRoss Abrams-9/19/1996
47 Good post, thanks for the info. The stock seems to be trading up abit today (lDoug Meetmer-9/19/1996
46 According to my forecasts, the CMV indication for cidofovir is worth at least $Ed Roach-9/18/1996
45 I just read the story on DJ wire about the patient who died while on Vistide. Doug Meetmer-9/18/1996
44 Excellent post!! This company is one of the strongest companies in business foDoug Meetmer-9/18/1996
43 I attempted to call the company today but the PR rep was busy or something likDoug Meetmer-9/18/1996
42 Gilead fell shortly after the market opened to a low of $25. There was a big bJohn Metcalf-9/17/1996
41 The BAD news is that toxicity of Vistide was noticed in two patients according phbolton-9/17/1996
40 Why is it down after two days of good news (the hepatitis news yesterday)??? I phbolton-9/17/1996
39 John, today Gilead had a fairly positive announcement that they are studying aDoug Meetmer-9/17/1996
38 New Eng. J. Med. 335, 625 (1996) "Association between prior CMV infection phbolton-9/2/1996
37 Thanks for the NY Times article info. Interesting to say the least. Who woulda Mark Nelson-9/2/1996
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News